Phase 1 Study of Suizenji Ultrasound-Guided HIFU Ablation for Unresectable Pancreatic Cancer

This open-label, non-randomized single-center study sponsored by SONIRE Therapeutics Inc. is evaluating the feasibility, safety, tolerability, and preliminary efficacy of Suizenji, an ultrasound-guided high-intensity focused ultrasound device that thermally ablates pancreatic tumor tissue. The protocol also explores combination treatment with liposomal irinotecan (a topoisomerase I inhibitor) and mFOLFOX-6 in patients with unresectable pancreatic ductal adenocarcinoma.